LOS ANGELES, Oct. 29, 2014 /PRNewswire/ -- ViaDerma, Inc.
(OTCQB: VDRM), a specialty pharmaceutical company devoted to
bringing new products to market, is committed to pursuing
out-licensing partnerships in 2015.
ViaDerma has developed an innovative, patent-pending dual
carrier transdermal delivery method, which allows for rapid mass
transfer of pharmaceutical active ingredients to penetrate the skin
and into the body to provide immediate localized therapy. The
transdermal delivery method also overcomes microbial drug
resistances, which the Company believes will prolong the viability
of antibiotics for years to come. The company has potential to pair
this technology with a wide variety of active ingredients to
develop new antimicrobial drugs with pharmaceutical companies that
license from ViaDerma.
"This delivery system is unique in the market. It was originally
developed to treat diabetes foot wounds, but the technology worked
so well that physicians came to us and asked if we could use it for
other indications," said Dr. Christopher
Otiko, CEO of ViaDerma. "We are excited to pursue
partnerships and license our technology to combine with existing
medications."
In the coming months, ViaDerma will be dedicated to research and
development, growing market awareness and actively seeking
licensing opportunities in order to expand business development and
distribution for this technology in 2015. The Company believes its
technology may be applicable in many fields including: sports
nutrition supplements, cosmetics, first-aid products, wound care
and various skin diseases such as: acne, eczema and psoriasis.
About ViaDerma, Inc.
Founded in 2014 by Dr.
Christopher Otiko, ViaDerma, Inc.
(VDRM) is a publicly traded specialty pharmaceutical company
committed to bringing new products to market and licensing its
innovative technology to current leaders in the pharmaceutical
industry in a wide variety of therapeutic areas. ViaDerma's lead
product, TetraStem, uses an innovative transdermal delivery method
to apply almost any active ingredient to a topical drug. This
patent-pending dual carrier transdermal technology may be applied
in products within the medical and cosmetic markets. For more
information, please visit www.viadermalicensing.com.
Contact
Dr. Christopher
Otiko
Chief Executive Officer
ViaDerma, Inc.
info@viadermalicensing.com
818-836-2475
Kristi Hofacker
Director of Interactive Marketing & Media
The Brewer Group
kristi.hofacker@thebrewergroup.com
Forward Looking Statements
This press release
contains forward-looking statements that involve a number of risks
and uncertainties, including statements regarding the outlook of
the Company's business and results of operations. By nature, these
risks and uncertainties could cause actual results to differ
materially from those indicated. Generally speaking, any statements
using terms such as "will," "expect," "anticipate," or "may," or
which otherwise predict or address future results or events, are
likely to contain forward-looking statements. It is important to
note that actual results may differ materially from what is
indicated in any forward-looking statement. Readers should consider
any forward-looking statements in light of factors that could cause
actual results to vary. These factors are described in our filings
with the SEC, and readers should refer to those filings,
including Risk Factors described in those filings, in connection
with any forward-looking statements. The Company disclaims any
intention or obligation to update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise.
SOURCE ViaDerma, Inc.
